ReviewMolecular biology reports2025
The integrin-matrix-FAK-EMT axis in Anoikis resistance: a critical network in tumor progression and therapy.
Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Partial FAK suppression promotes tumor growth, an effect reversed by macrophage p110δ PI3K inactivation.Molecular oncology · 2026Article
- Programmed cell death and metastatic evolution in breast cancer: the role of anoikis, necroptosis, and ferroptosis.Apoptosis : an international journal on programmed cell death · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anoikis (or cell detachment-induced apoptosis) is a mechanism used by organisms to protect themselves and eliminate "misplaced" cells in an inappropriate location. This mechanism is critical for maintaining tissue integrity and preventing cell migration. However, cancer cells resist anoikis and survive through metastasis. Elucidating the molecular mechanisms of anoikis resistance will lead to important potential strategies against cancer migration and metastasis, the epithelial mesenchymal transition (EMT) process, cell-cell junctions, and ECM-cell interactions, as well as the identification of personalized treatment options. In this review, we summarize the mechanisms of anoikis/anoikis resistance. We highlight recent advances in anoikis and how anoikis resistance manifests in normal and cancer cells. We also briefly discuss compounds targeting anoikis resistance, including nanoparticles, nanotherapies, and chemical inhibitors, and explain how emerging data can benefit treatment strategies. We highlight the techniques used in in vitro and in vivo models for the study of anoikis resistance, which play a significant role. Our overall goal is to pioneer studies targeting anoikis resistance, which plays a role in cancer metastasis, and to guide developments in treatment strategies and personalized patient-focused inference perspectives, which are expected to gain increasing importance in the coming years.
Indexed as
Identifiers
41284137What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.